Down 30% in 6 Months: Is Tilray Still a Buy?
The Canadian cannabis company Tilray (NASDAQ: TLRY) hasn't been the best performer over the last six months, with its shares falling by more than 31% while the larger market rose by 14%. Of course, over the last 12 months, its stock has grown by 50%, surpassing the market's 31%, making its recent pullback all the more intriguing for investors.
Is Tilray on track to be a strong performer in 2022, or is its tenuous positioning relative to the rapidly opening U.S. cannabis market going to be a problem? As it turns out, both of these things can be true.
Image source: Getty Images.
Source Fool.com
